Vybion Signs Agreement in Principle to Sell Line of Recombinant Proteins to Meridian Bioscience

Vybion Signs Agreement in Principle to Sell Line of Recombinant Proteins to Meridian Bioscience

ITHACA, N.Y. -- Vybion, Inc., an Ithaca-based biotechnology company, today announced that it has executed a letter of intent to sell its recombinant protein business to Meridian Bioscience, Inc. (NASDAQ: VIVO). The planned transaction, which both Vybion and Meridian expect will be completed within the next 60 days, calls for Vybion to receive both cash and future royalties based on sales of the applicable products, the amounts of which were not disclosed. Completion of the transaction is subject to execution of a definitive purchase agreement, satisfactory due diligence, and other customary conditions.

Dr. Lee Henderson, founder and CEO of Vybion, explained "This is an excellent opportunity for both companies. For Vybion it means that we can focus and internally fund proprietary activities, namely moving CoMab, our monoclonal antibody preclinical drug for Cocaine abuse, forward and commercialize our ProCode Platform technology.

Suggested Articles

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.